Literature DB >> 3474147

Failure of gallium-67 citrate imaging to diagnose post-myocardial infarction (Dressler's) syndrome.

S J Hutchison, J H McKillop, I Hutton.   

Abstract

Gallium-67 scanning has been suggested as a means of diagnosing post-pericardiotomy syndrome. We have assessed the value of thoracic gallium scanning in patients with the post-myocardial infarction (Dressler's) syndrome, which is thought to have a similar pathogenesis. In five patients in whom the diagnosis was established by currently available means, 67Ga scans performed during active pericarditis showed no significant uptake in any case. No subject was receiving steroids but all were taking non-steroid anti-inflammatory drugs at the time of scanning. It is not clear why there should be differences in gallium uptake between the two conditions, but we conclude that 67Ga thoracic scanning is of no value in the management of patients with Dressler's syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474147     DOI: 10.1007/BF00252647

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  5 in total

1.  The post-myocardial-infarction syndrome: a report on forty-four cases.

Authors:  W DRESSLER
Journal:  AMA Arch Intern Med       Date:  1959-01

2.  Evidence for the continued existence of the postmyocardial infarction (Dressler's) syndrome.

Authors:  R J Northcote; S J Hutchison; J B McGuinness
Journal:  Am J Cardiol       Date:  1984-04-01       Impact factor: 2.778

3.  Gallium-67 scanning: a new diagnostic approach to the post-pericardiotomy syndrome.

Authors:  V J Bufalino; J A Robinson; R Henkin; J O'Connell; R Gunnar
Journal:  Am Heart J       Date:  1983-11       Impact factor: 4.749

Review 4.  Gallium and infection.

Authors:  P Hoffer
Journal:  J Nucl Med       Date:  1980-05       Impact factor: 10.057

5.  Current incidence of postmyocardial infarction (Dressler's) syndrome.

Authors:  E Lichstein; E Arsura; G Hollander; A Greengart; M Sanders
Journal:  Am J Cardiol       Date:  1982-12       Impact factor: 2.778

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.